clairop

Do FODMAP Enzymes Work? What the Trials Show

Some FODMAP enzymes have small trials behind them, others only lab data. What lactase, alpha-galactosidase and fructan enzymes show, and what they cannot do.

Clairop Team23 min read

Photo: Apartment Life / Unsplash

The short answer

Partly, and only for some FODMAPs. Small trials support alpha-galactosidase for GOS in people with IBS, lactase for lactose and xylose isomerase for fructose. Fructan enzymes have lab data and healthy-volunteer trials, not IBS trials yet. No oral enzyme for polyols was found. Enzymes are not a substitute for reintroduction, and none should be started or stopped without clinician advice.

Trying to find your triggers? Clairop logs meals, symptoms and stool in seconds on iPhone, then flags foods your gut reacts to, including delayed reactions.

Get it on the App Store

Do FODMAP digestive enzymes actually work?

Partly. For some FODMAPs, in small trials, there is real evidence that a matched enzyme reduces symptoms. For others it is laboratory work or healthy-volunteer data, and for polyols none turned up. "Do FODMAP enzymes work" is really six different questions, one per enzyme, and the honest answer changes with each.

It helps to know why anyone is asking. The low FODMAP diet is the dietary approach the American College of Gastroenterology recommends as a limited trial for IBS (Lacy 2021). It works by restricting a family of fermentable carbohydrates, then reintroducing them one group at a time to find which ones are yours (Whelan 2018). That process is tiring, and it is not meant to last forever. The appeal of an enzyme is obvious: break the carbohydrate down before it reaches the colon, and eat the pizza, the onion sauce or the bean chilli at a friend's table.

A theme that comes up again and again in r/FODMAPS is exactly this longing for normal social meals, and also fatigue with the cost. In a thread where a one-person company announced a new enzyme powder, the top comments were about price, shipping to other countries and whether it could be tested for contaminants. In another thread reviewing a pill-format competitor, several people simply asked whether the post was an advert. None of that is evidence about whether the products work, and I am not using it as such. It is a useful reminder that this is a marketplace with strong claims and uneven proof, and a good reason to look at what has actually been tested.

This article covers what the trials say, enzyme by enzyme, what the product pages we could read actually claim, whether enzymes can stand in for reintroduction, and the safety questions nobody has fully answered yet. It is written for people with IBS. If you have Crohn's disease or ulcerative colitis, the short answer is that there is no trial evidence in your conditions at all, and there is a section further down for you.

Which enzymes target which FODMAPs?

Each enzyme breaks down one kind of carbohydrate. An enzyme for lactose does nothing for garlic, and an enzyme for fructans does nothing for sorbitol.

FODMAP subgroupEnzyme that acts on itTypical foodsPublished human trial found
LactoseLactaseMilk, soft cheese, yogurtYes, in lactose intolerance
GOS (galacto-oligosaccharides)Alpha-galactosidaseBeans, lentils, chickpeasYes, in IBS
FructansFructan hydrolase, such as inulinaseWheat, onion, garlicHealthy volunteers only
Excess fructoseXylose isomeraseHoney, apple, mangoYes, in fructose malabsorption
PolyolsNone identifiedSorbitol, mannitol, stone fruit, mushroomsNone found

Three things in that table deserve plain language.

First, matching matters. Products often combine several enzymes, but the label does not tell you which of the six FODMAP subgroups your own symptoms come from. Someone whose trigger is sorbitol in sugar-free gum gains nothing from a lactase, GOS and fructan blend. Someone whose trigger is garlic gains nothing from a lactase tablet. If you want the chemistry of why garlic and onion are so potent, see why garlic and onion affect IBS. If your issue is dairy and lactose-free milk still upsets you, that article covers why lactase is not the whole story.

Second, "none identified" is a statement about my search, not about the future. I searched PubMed and Europe PMC for oral enzymes for polyols and for trials of oral enzymes across FODMAPs and found nothing for polyols. A product maker in the r/FODMAPS launch thread said polyols have not been solved as an oral enzyme supplement, which fits what I found, though a product maker's comment is a claim, not evidence. If a polyol enzyme appears later, the position changes.

Third, fructan hydrolase has an inconvenient by-product. It converts fructans into fructose. In a laboratory gut model, roughly 70% of the fructose released was absorbed during simulated small-intestinal transit (Ochoa 2023). That is a simulation. In people, fructose is itself a FODMAP, and in one clinic series of 186 people with IBS who had breath tests, 38.2% were positive for fructose malabsorption and 48.9% for fructan malabsorption, with the two significantly associated, and people positive for one having 1.951 times the odds of being positive for the other (Sia 2024). This was a retrospective single-center study, so treat the figures as indicative. The practical point is that for someone who also struggles with fructose, converting fructan into fructose might not be a clean win. Nobody has tested that in a trial.

What do the trials show?

Four human trials in IBS or malabsorption populations are the best evidence, and all are small. The fructan enzyme data are mostly laboratory or healthy-volunteer work. Here they are one at a time, with their limits stated.

Alpha-galactosidase for GOS in IBS (Tuck 2018)

This is the closest thing to a clean IBS trial in the whole field. It was a randomized, double-blind, placebo-controlled crossover study in patients meeting Rome III criteria who were hydrogen producers on breath testing. Participants did a 3-day low FODMAP run-in, then 3 days of provided diets high in GOS and low in other FODMAPs, once with full-dose enzyme, once with half-dose and once with placebo. Thirty-one people completed it. Adding GOS foods significantly raised symptoms overall, and 21 people were GOS-sensitive, defined as a rise of more than 10 mm on a 100 mm scale. In those 21, the full-dose enzyme reduced overall symptoms (median 24.5 mm versus 5.5 mm, P = 0.006) and bloating (P = 0.017). Breath hydrogen did not differ between placebo and full dose (Tuck 2018).

What it tells you: if you are GOS-sensitive, a matched enzyme can help in a controlled setting. What it does not: the diets were supplied and designed to contain mainly GOS, which real meals rarely do. It ran for 3 days per arm. Ten of the 31 were not GOS-sensitive, which is an argument for finding out whether GOS is your trigger before buying anything. The authors concluded it could be used as an adjunct to the low FODMAP diet, not a replacement.

Lactase for lactose intolerance (Baijal 2021)

Lactase has the longest history. A randomized, double-blind, crossover, placebo-controlled study in 47 adults with lactose intolerance confirmed by hydrogen breath test found that lactase chewable tablets improved clinical symptom scores and reduced cumulative breath hydrogen by 55% over 180 minutes compared with placebo (Baijal 2021).

The limits: this was lactose intolerance, not IBS. It was a single test session per arm with a one-week washout, so it says nothing about months of use. The sample was 47. Lactase is a mainstream, well-understood enzyme, but the question of whether it works for you depends on whether lactose is really the problem, which is not always the case. If you are already lactose-free and still symptomatic, the issue is likely elsewhere.

Xylose isomerase for fructose (Komericki 2012)

A double-blind placebo-controlled study of 65 patients with fructose malabsorption diagnosed by breath test within the previous year gave 25 g of fructose in 100 mL of water with either placebo or xylose isomerase. Median breath hydrogen area under the curve was 885 ppm per 240 minutes with the enzyme and 2071 with placebo. Abdominal pain and nausea were significantly improved, while bloating was not (P = 0.053) (Komericki 2012).

The limits: a watery fructose drink is not a meal. It was one challenge, in a population with diagnosed malabsorption rather than a general IBS group, and the study can only speak to that enzyme in that setting. It does not tell you whether a given commercial blend contains a comparable enzyme.

Fructan enzymes: laboratory, safety and one healthy-volunteer trial

This is where most commercial products sit, and the evidence is the thinnest relative to the marketing. There are three pieces.

A laboratory gut model. In a simulator of the human intestinal ecosystem, a fructan-hydrolase product converted 90% of a 3 g inulin load to fructose after 30 minutes, with a lower amount of product performing worse (77.2%) and a higher amount giving no significant improvement. Gas production fell and short-chain fatty acid output was largely preserved (Ochoa 2023). That is a mechanism demonstration in a machine.

A safety trial in healthy adults. Sixty healthy adults took an inulinase or placebo capsule with meals for 4 weeks. Blood chemistry, hematology and symptom scores showed no clinically meaningful differences, and adverse events were reported by 5 of 30 in the inulinase group and 8 of 30 in the placebo group (Garvey 2024). It was designed to test safety, not benefit, and its authors said a dose-ranging study in people with fructan sensitivity or IBS was warranted. The authors were affiliated with an enzyme manufacturer, which is not unusual for this kind of trial but is worth knowing.

A symptom trial in healthy adults. A 2026 randomized, double-blind crossover trial of 30 healthy adults gave 25 g of inulin in oatmeal with either a fructanase capsule or placebo. The primary 0 to 8 hour overall abdominal symptom score was not statistically significant (P = 0.13). Secondary results favored the enzyme: less abdominal pain and fatigue in the first 8 hours, and over 8 to 24 hours less overall abdominal symptoms, bloating, abdominal pain and flatulence. Breath hydrogen and methane did not differ between groups (Mah 2026). The authors called for trials in people with GI symptoms such as IBS.

Reading that honestly: the headline outcome missed significance, several secondary outcomes did not, and with many outcomes tested some could be chance. The participants had no IBS. A 25 g inulin load is a challenge dose, not a plate of pasta. This is encouraging but preliminary.

An uncontrolled real-world study

A single-arm, open-label study followed people who had purchased a FODMAP-targeting enzyme blend online and completed anonymous surveys at baseline and 4 weeks. Of respondents, 78.0% reported improved bloating and flatulence and 65.3% reported improved abdominal pain, with significant improvements in overall IBS symptom severity and quality of life (Kaye 2026). The authors themselves described it as a promising first report requiring further research.

This design cannot tell you whether the enzyme did the work. There is no placebo group, and people who buy a product and answer a survey are not a random sample. Expectation matters a great deal in IBS, which is why placebo-controlled designs exist. I would treat it as a hypothesis generator.

What the evidence adds up to

  • Matched, single-subgroup enzymes (GOS, lactose, fructose) have small controlled trials with signals of benefit.
  • Fructan enzymes have strong mechanism data and plausible but preliminary human data, mainly in people without IBS.
  • Combination products have, as far as I found, no published controlled trial in IBS.
  • Nothing here is long-term. No trial followed anyone for months.
  • Nothing here is in Crohn's disease or ulcerative colitis.

Are FODZYME and similar products worth it?

I cannot tell you that, and nobody can on the published evidence alone. What I can do is describe what the pages I read actually say, so you can judge claims against evidence. This section describes only what I could verify from product pages fetched while writing this article. It is not an endorsement or a recommendation to start or avoid any product, and it contains no dosing and no prices.

FODZYME. Its homepage describes a tasteless powder added to food using "novel, patent-pending enzymes" and does not name them there. It links particular foods to FODMAP groups: wheat bread, wheat pasta, onion and beans for fructans and GOS, and cheese for lactose. It describes the product as "clinically validated" without giving study details on that page, shows a Monash University Low FODMAP Certified logo, and carries the standard statement that the product has not been evaluated by the US Food and Drug Administration and is not intended to diagnose, treat, cure or prevent any disease (FODZYME). A company blog post on the certification quotes Monash as having assessed the product as low in FODMAPs only, and that a serve can assist with following the low FODMAP diet (FODZYME on Monash certification).

That certification matters but is easy to misread. By the company's own account it speaks to what is in the product, not to whether the product works. The founder of a newer competitor said much the same in the r/FODMAPS launch thread, describing disappointment that certification confirms an absence of FODMAPs, not effectiveness. Published research on the FODZYME formulation is the laboratory model described above (Ochoa 2023). A real-world survey of an unnamed FODMAP-targeting blend (Kaye 2026) shares authors with that laboratory paper, though its abstract does not name the product. I did not find a randomized controlled trial of this specific product in people with IBS. Clairop is not affiliated with Monash University or any of these companies.

Fodease. Its product page lists three enzymes with activity units per serving (lactase, inulinase and alpha-galactosidase) and says it targets fructans, lactose and GOS. The page I fetched contained no trial or certification claims and no dietary disclaimer, though it linked to a lab-testing page I could not read (Fodease). In the launch thread, the maker said that third-party testing for heavy metals had been started, that Monash and FODMAP Friendly certification were not yet in place, and that no supplement works for everyone. That is a seller speaking about its own product, so weigh it accordingly.

A reasonable set of questions to ask of any enzyme product, from the page or from the maker:

  1. Which FODMAP subgroups does it claim to cover, and which enzyme is responsible for each?
  2. Is there a controlled trial of this formulation, in whom, and who ran it?
  3. Is the evidence about this product, or about a similar enzyme made by someone else?
  4. What else is in it? Several commenters in the review thread asked about botanical extracts in one product's base, including one that is a fructan source and another with a known concern for some medical conditions. If you take medication or have a condition such as high blood pressure, read the full ingredient list and ask a pharmacist or doctor.
  5. Has the manufacturer published independent contaminant or quality testing?
  6. What does it say about who should not use it, and does it point you to a clinician?

Notice that none of those questions is "do people like it". Reviews on the internet are largely self-selected, and as the community itself keeps noting, some of them are marketing.

Can enzymes replace reintroduction?

No. Reintroduction answers "which FODMAPs trigger me, and in what amount?" and an enzyme answers a different question: "can I get away with a trigger I already know about?" They are sequential, not interchangeable.

The low FODMAP diet is described in the clinical literature as three stages: restriction, reintroduction and personalization. The goal is a less restrictive long-term diet that excludes only your personal triggers and keeps dietary variety (Whelan 2018). A UK consensus group recommended that dietary therapies for IBS be offered by dietitians (Rej 2022). A review of dietary management also flags that restrictive whole-diet interventions can be hard to deliver safely, with concern about eating disorder risk (Whelan 2024). That last point deserves more attention than it gets in the enzyme conversation: an enzyme is sometimes presented as a way to avoid restriction, but it can just as easily become a way to keep avoiding food groups by default.

Here is why an enzyme cannot do reintroduction's job:

  • It only covers some subgroups. If your real trigger is a polyol, an enzyme blend of lactase, GOS and fructan enzymes will look like it "failed", and you may wrongly conclude FODMAPs are not your problem.
  • It confounds the test. If you reintroduce wheat while also taking a fructan enzyme and feel fine, you have learned that wheat plus enzyme is fine, which is not the same as learning your fructan tolerance. If you feel unwell, you cannot tell whether the dose was too big for the enzyme or whether another component was responsible.
  • Not everyone is sensitive to each group. In the GOS trial, 21 of 31 were GOS-sensitive. A third were not (Tuck 2018). Taking an enzyme for a FODMAP that never bothered you is a cost with no benefit.
  • One bad meal is not proof. Blinded reintroduction research shows that placebo reactions are common, and the same applies to a good meal with an enzyme: a result from one plate is thin. The step-by-step method for a fair test is in how to reintroduce foods after the low FODMAP diet.

Where an enzyme could fit, as an idea to discuss with your dietitian rather than a plan, is after reintroduction. Once you know which subgroups are your triggers, and at what quantities, a conversation about whether an enzyme matched to one of them might help in a specific situation, such as a meal you cannot control, becomes much more informed. The 2018 GOS trial authors framed the idea the same way, as an adjunct to the diet (Tuck 2018). For the eating-out side of that problem, eating out low FODMAP covers the practical tactics that do not depend on a supplement.

Are they safe?

Short-term safety data in healthy adults are reassuring. Long-term data, data in IBS, and data in inflammatory bowel disease are largely missing. Enzymes are proteins that are broken down in digestion, which is part of why they are usually thought of as low risk, but "usually thought of" is not the same as "studied".

What we know:

  • A 4-week randomized placebo-controlled trial of a microbial inulinase in 60 healthy adults found no clinically meaningful differences in blood chemistry, hematology, lipids, inflammation markers or symptom scores, with similar rates of adverse events in both groups (Garvey 2024).
  • The lactase, alpha-galactosidase and xylose isomerase trials above were single-session or a few days long and did not set out to assess long-term safety (Baijal 2021; Tuck 2018; Komericki 2012).

What we do not know:

  • What happens with daily use over months or years.
  • Whether using enzymes affects how people eat, for example by making them less willing to reintroduce foods.
  • Whether anything changes in people with active inflammatory bowel disease, with strictures, or on other medicines.
  • Whether commercial products match the enzymes and activities used in trials. Supplements are not evaluated by regulators in the way medicines are, and the FODZYME page itself carries the standard US disclaimer to that effect.

Ask your doctor, dietitian or pharmacist before using any supplement, particularly if you have other health conditions, are pregnant or take other medicines. Nothing in this article is advice to start, stop or change a supplement or medicine.

A community question that repeatedly turns up, including in the review thread, is whether long-term use carries risks and whether a doctor gave guidance. That is the right question and, today, the honest answer is that the long-term data do not exist yet.

Do FODMAP enzymes work if you have Crohn's or ulcerative colitis?

There is no trial evidence for FODMAP enzymes in Crohn's disease or ulcerative colitis. The trials above enrolled people with IBS, healthy volunteers, or people with lactose or fructose malabsorption.

Many people with inflammatory bowel disease have IBS-type symptoms during remission, and food can matter. But ongoing symptoms in IBD should always be checked against disease activity rather than assumed to be food, and that is a conversation for your IBD team. If you have a stricture, texture and fiber are separate considerations that need your team's input before you change what you eat. The relevant background is in the low FODMAP diet and Crohn's disease and low FODMAP for ulcerative colitis.

When should you see a doctor while taking enzymes?

Enzymes address one narrow mechanism. They do not address everything else that can go wrong in the gut. See a doctor promptly if you have:

  • Blood in your stool, or black tarry stools
  • Unexplained weight loss
  • A fever alongside gut symptoms
  • Symptoms that wake you from sleep
  • Anemia, or symptoms of it such as unusual breathlessness or tiredness
  • New bowel symptoms starting after age 50
  • A family history of bowel cancer, celiac disease or inflammatory bowel disease

The ACG guideline suggests a positive diagnostic strategy for IBS, serology to rule out celiac disease in people with diarrhea-predominant symptoms, and fecal calprotectin to help rule out IBD in suspected IBS with diarrhea (Lacy 2021). The BSG guideline likewise frames IBS as a disorder of gut-brain interaction diagnosed on a structured assessment (Vasant 2021). If you have not had that assessment, no enzyme is a substitute for it. A swelling of the lips or face, hives or trouble breathing after eating is an emergency and needs urgent care, not a supplement.

Myths about FODMAP enzymes

"A Monash-certified enzyme is proven to work." The certification, by the company's own description of it, says the product is low in FODMAPs. It is about content, not effectiveness.

"One enzyme covers every FODMAP." No published trial shows that, and I found no enzyme for polyols at all. Each enzyme matches one subgroup.

"If I take an enzyme I do not need to reintroduce." Reintroduction is how you find out which enzyme, if any, is worth discussing. Skipping it is how people end up buying products for FODMAPs that never bothered them.

"Natural enzymes are automatically safe long term." They might be, but that has not been shown. Short-term data in healthy adults are reassuring, and long-term data are absent.

"The studies prove it, because the survey said 78% improved." An uncontrolled survey of purchasers cannot separate the product from expectation, natural fluctuation or other changes in diet (Kaye 2026).

"Enzymes mean I never have to think about food again." The people who run these companies do not say so either. One maker in the launch thread described the product as a tool for specific FODMAPs, not a license to eat anything.

A worked example: a structured way to approach the question

Imagine someone who finished the elimination phase of the low FODMAP diet, did reintroduction with a dietitian, and found that garlic and onion (fructans) trouble them at quantities that crop up in restaurant food, while lactose and GOS foods do not. Here is how the enzyme question might be framed for them, as a conversation not a prescription.

  1. Name the trigger. Fructans, established through reintroduction, not a guess.
  2. Ask whether an enzyme matches it. Fructan hydrolase does, on the laboratory and healthy-volunteer evidence, and no IBS trial yet.
  3. Compare the evidence honestly. Encouraging mechanism, a mixed primary outcome in healthy adults, an uncontrolled real-world survey.
  4. Ask a clinician about safety and fit for their particular health and medicines.
  5. If they decide to try one, treat it as a planned, time-limited test, not an open-ended habit: note which meals included it, what else was eaten, and what happened afterwards. Decide beforehand what would count as helpful, so the answer is not shaped by hope.
  6. Review with the dietitian. If the test is unclear, that is a result too.

None of that is advice for any particular person to buy anything. It is a template for turning "do FODMAP enzymes work?" into "did this work for me, on this trigger, in this setting?".

How can you tell whether an enzyme is helping?

The hardest part of testing an enzyme is that symptoms are delayed. FODMAP fermentation can produce effects hours later, and the fructanase trial reported its clearest benefits in the 8 to 24 hour window (Mah 2026). A single "I felt fine after dinner" can be misleading.

Clairop is a free-to-download iPhone app (using it needs a Clairop Pro subscription) that logs meals by tap, voice, a typed sentence or a photo, alongside one-tap stool entries and symptoms. Its trigger analysis tests each food in three windows, under 6 hours, 6 to 24 hours and 1 to 3 days, and shows nothing for a food until you have logged at least 5 meals with it and 5 without. It does not test enzymes as such, so if you use one, note it in the meal entry and tell your dietitian. It is not a medical device, not clinically validated, not diagnostic and iPhone only; the details are on the how it works and method pages.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Whether you use an app or a paper diary, the principle is the same: record what you ate, whether an enzyme was part of it, and what happened across the next day or so, then look for patterns across many meals rather than one.

The short version

  • Do FODMAP enzymes work? Some do, for some FODMAPs, in small trials. Others have promising mechanism data but little human evidence.
  • No enzyme covers polyols, and no product has been shown to cover everything.
  • Certification means low FODMAP content, not proven effect.
  • Enzymes sit after reintroduction in the logic of the diet, not instead of it.
  • Long-term safety is unknown, and there is no evidence in Crohn's or colitis.
  • Talk to a doctor or dietitian before using any supplement, and see a doctor promptly for blood in stool, weight loss, fever or night-time symptoms.

Where the questions come from

The r/FODMAPS threads this article drew on were a launch announcement for a new enzyme powder and a review comparing two enzyme products. I used them only to understand what people ask: how enzymes differ, why there is nothing for polyols, whether certification means effectiveness, what is in the base of a product, whether it is an advert, and whether long-term use is safe. Every medical statement above comes from the cited papers, not from the threads.

Frequently asked questions

Do FODMAP digestive enzymes actually work?
For some FODMAPs, in small trials, yes. In people with IBS who were sensitive to GOS, an alpha-galactosidase enzyme reduced overall symptoms and bloating versus placebo. Lactase reduced symptoms and breath hydrogen in lactose intolerance. For fructans, evidence so far is laboratory data plus healthy-volunteer trials, and no enzyme has been shown to cover all FODMAPs. Results vary between people.
Which enzyme goes with which FODMAP?
Lactase acts on lactose, alpha-galactosidase on galacto-oligosaccharides (GOS), fructan hydrolases such as inulinase on fructans, and xylose isomerase on fructose. I found no published trial of an oral enzyme for polyols such as sorbitol or mannitol. A product only helps with the subgroup its enzyme matches, so a mismatch between enzyme and your trigger does nothing.
Do FODMAP enzymes work for fructans?
The evidence is early. A fructan-hydrolase product converted about 90% of an inulin load to fructose in a laboratory gut model, and a 2026 crossover trial in 30 healthy adults found fewer symptoms from 8 to 24 hours after an inulin challenge. The main 0 to 8 hour symptom score was not significant, and trials in people with IBS are still called for.
Can FODMAP enzymes replace the reintroduction phase?
No. Reintroduction is how you learn which FODMAP subgroups bother you and at what amounts, and an enzyme answers a different question. Only some subgroups have enzymes, so an enzyme can mask or confuse a food test. The low FODMAP diet is meant to be a structured process with reintroduction and personalization, ideally guided by a dietitian.
Are FODMAP enzyme supplements safe?
Short-term safety data are reassuring but narrow. A 4-week trial of a microbial inulinase in 60 healthy adults found no meaningful differences in blood markers or symptoms versus placebo. I found no long-term data and no trials in Crohn's or colitis. Ask your doctor, dietitian or pharmacist before using any supplement, especially with other conditions or medicines.
Is FODZYME worth it?
That depends on whether your triggers match what it targets and on your budget, and I cannot judge either for you. Its site ties it to fructans, GOS and lactose and shows a Monash low FODMAP certification, which Monash says means low in FODMAPs only, not proven benefit. Published work is a lab model and an uncontrolled real-world survey, not a controlled trial in IBS.
What's the best FODMAP enzyme?
There is no evidence-based best product. Trials test specific enzymes against specific FODMAPs, and no head-to-head comparison of commercial blends exists. A sensible first question is which of your triggers an enzyme matches. If you are unsure, a dietitian can help work out which FODMAP subgroups bother you before anyone buys anything.
What's the best way to tell if an enzyme is helping?
Clairop logs each meal with the stool, symptom and timing data around it and tests foods across three windows (under 6 hours, 6 to 24 hours, 1 to 3 days), so you can see whether a food you ate with an enzyme behaved differently. It is not clinically validated and shows nothing until you have 5 meals with and 5 without a food. Bring the results to your dietitian.
Do enzymes work for polyols or fructose?
Fructose has one placebo-controlled trial of oral xylose isomerase in 65 people with diagnosed fructose malabsorption, which lowered breath hydrogen and abdominal pain after a 25 g fructose drink. For polyols (sorbitol, mannitol and similar) I found no published trial of an oral enzyme, so enzyme products do not currently address them.
Do FODMAP enzymes work for Crohn's disease or ulcerative colitis?
There is no trial evidence in Crohn's or colitis. The studies above were in IBS, healthy volunteers or lactose and fructose malabsorption. Gut symptoms in IBD need checking against disease activity first, so please speak to your IBD team before trying any supplement. See a doctor promptly for blood in stool, weight loss, fever or night-time symptoms.

Sources

  1. Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036
  2. Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet. 2018;31(2):239-255. doi:10.1111/jhn.12530
  3. Tuck CJ, Taylor KM, Gibson PR, Barrett JS, Muir JG. Increasing symptoms in irritable bowel symptoms with ingestion of galacto-oligosaccharides are mitigated by alpha-galactosidase treatment. Am J Gastroenterol. 2018;113(1):124-134. doi:10.1038/ajg.2017.245
  4. Baijal R, Tandon RK, et al. Effect of lactase on symptoms and hydrogen breath levels in lactose intolerance: a crossover placebo-controlled study. JGH Open. 2021;5(1):143-148. doi:10.1002/jgh3.12463
  5. Komericki P, Akkilic-Materna M, Strimitzer T, Weyermair K, Hammer HF, Aberer W. Oral xylose isomerase decreases breath hydrogen excretion and improves gastrointestinal symptoms in fructose malabsorption: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2012;36(10):980-987. doi:10.1111/apt.12057
  6. Mah E, McKenna CF, Blonquist TM, et al. Oral fructanase administration reduces gastrointestinal symptom severity after acute inulin challenge in healthy adults. J Nutr. 2026;156(10):101782. doi:10.1016/j.tjnut.2026.101782
  7. Garvey SM, LeMoire A, Wang J, et al. Safety and tolerability of microbial inulinase supplementation in healthy adults: a randomized, placebo-controlled trial. Gastro Hep Adv. 2024;3(7):920-930. doi:10.1016/j.gastha.2024.05.013
  8. Ochoa KC, Samant S, Liu A, et al. In vitro efficacy of targeted fermentable oligosaccharides, disaccharides, monosaccharides, and polyols enzymatic digestion in a high-fidelity simulated gastrointestinal environment. Gastro Hep Adv. 2023;2(3):283-290. doi:10.1016/j.gastha.2022.10.011
  9. Sia T, Tanaka R, Mousa A, et al. Fructose malabsorption and fructan malabsorption are associated in patients with irritable bowel syndrome. BMC Gastroenterol. 2024;24(1):143. doi:10.1186/s12876-024-03230-x
  10. Kaye AJ, Meyers SR, Hachuel D, Wells J, Wallach T, Thor S. FODMAP-targeting digestive enzyme blend for management of gastrointestinal symptoms: a real-world pre-post intervention cohort study. Gastro Hep Adv. 2026;5(4):100898. doi:10.1016/j.gastha.2026.100898
  11. Rej A, Avery A, Aziz I, et al. Diet and irritable bowel syndrome: an update from a UK consensus meeting. BMC Med. 2022;20(1):287. doi:10.1186/s12916-022-02496-w
  12. Whelan K, Ford AC, Burton-Murray H, Staudacher HM. Dietary management of irritable bowel syndrome: considerations, challenges, and solutions. Lancet Gastroenterol Hepatol. 2024;9(12):1147-1161. doi:10.1016/s2468-1253(24)00238-3
  13. Vasant DH, Paine PA, Black CJ, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214-1240. doi:10.1136/gutjnl-2021-324598

Clairop is a general wellness app for people living with a diagnosed digestive condition. It does not replace professional medical care, diagnosis, or treatment. Always follow your healthcare provider's advice.

Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.

Download on the App Store

Apps for this, ranked

Free tools